Durect
- Country
- Ownership
- -
- Employees
- 58
- Market Cap
- -
- Introduction
DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment
- Conditions
- Alcoholic Hepatitis
- Interventions
- Drug: DUR-928 30 mgDrug: Placebo+ Standard of Care (SOC)Drug: DUR-928 90 mg
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Durect
- Target Recruit Count
- 307
- Registration Number
- NCT04563026
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸Mount Sinai Hospital, New York, New York, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Durect
- Target Recruit Count
- 2
- Registration Number
- NCT04447404
- Locations
- 🇺🇸
Site 03, Newark, New Jersey, United States
Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: DUR-928 Topical SolutionDrug: Vehicle Topical Solution
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- Durect
- Target Recruit Count
- 25
- Registration Number
- NCT03837743
- Locations
- 🇺🇸
Site 05, Tampa, Florida, United States
🇺🇸Site 02, Plainfield, Indiana, United States
🇺🇸Site 03, Spokane, Washington, United States
A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis
- Conditions
- Alcoholic Hepatitis
- Interventions
- Drug: DUR-928 90 mgDrug: DUR-928 150 mgDrug: DUR-928 30 mg
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Durect
- Target Recruit Count
- 19
- Registration Number
- NCT03432260
- Locations
- 🇺🇸
DURECT Study Site 0004, Atlanta, Georgia, United States
🇺🇸DURECT Study Site 0002, Chicago, Illinois, United States
🇺🇸DURECT Study Site 0005, Louisville, Kentucky, United States
A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)
- First Posted Date
- 2018-01-09
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Durect
- Target Recruit Count
- 5
- Registration Number
- NCT03394781
- Locations
- 🇺🇸
Charlotte Mecklenburg Hospital, Charlotte, North Carolina, United States
🇺🇸California Pacific Medical Center, San Francisco, California, United States
🇺🇸Southern Therapy and Advanced Research, Jackson, Mississippi, United States
Trial of Extended Release Bupivacaine for Pain Relief After Surgery
- Conditions
- Post Operative Pain
- Interventions
- Drug: SABER-Bupivacaine (Part 1)Drug: SABER-Bupivacaine (Part 2)Drug: Saline Placebo
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- Durect
- Target Recruit Count
- 399
- Registration Number
- NCT02574520
- Locations
- 🇺🇸
Durect Study Site 04, Florence, Alabama, United States
🇺🇸Durect Study Site 03, Sheffield, Alabama, United States
🇺🇸Durect Study Site 15, Fontana, California, United States
An Extension Trial to Evaluate Long-term Safety of SABER™-Bupivacaine for Pain Following Shoulder Surgery
- Conditions
- Pain
- First Posted Date
- 2010-06-09
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Durect
- Target Recruit Count
- 47
- Registration Number
- NCT01139866
Study of the Efficacy and Safety of Bupivacaine TTS Patch in Patients With Chronic Low Back Pain
- Conditions
- Chronic Low Back Pain
- Interventions
- Drug: Placebo patch
- First Posted Date
- 2010-03-31
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Durect
- Target Recruit Count
- 263
- Registration Number
- NCT01096966
Bupivacaine Effectiveness and Safety in SABER® Trial
- Conditions
- Postoperative PainAbdominal Surgery
- Interventions
- First Posted Date
- 2010-01-20
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- Durect
- Target Recruit Count
- 331
- Registration Number
- NCT01052012
- Locations
- 🇳🇿
DURECT Study Site, Christchurch, New Zealand
An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Undergoing Hysterectomy
- Conditions
- Postoperative Pain
- Interventions
- Drug: SABER-Bupivacaine Treatment 2aDrug: Placebo SABER-Bupivacaine Treatment 2bDrug: SABER-Bupivacaine Treatment 1aDrug: Placebo SABER-Bupivacaine Treatment 1b
- First Posted Date
- 2009-10-12
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- Durect
- Target Recruit Count
- 115
- Registration Number
- NCT00993226
- Locations
- 🇬🇧
Nycomed, London, United Kingdom